Gene study aims to personalize diabetes treatment

NCT ID NCT01762046

Completed Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how inherited gene variants influence the body's response to two common type 2 diabetes medications, metformin and glipizide. Over 1,000 participants took each drug and had their glucose and insulin levels measured. The goal was to understand why some people respond better than others, which could lead to more personalized treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin and glipizide
What this could lead to: If successful, this could help doctors personalize diabetes treatment based on a person's genes.
What could go wrong: This is a completed early-phase study focused on understanding genetics, not testing a new treatment. Results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02116, United States
Joslin Diabetes Center

Boston, Massachusetts, 02116, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.